![Bill Lundberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bill Lundberg
Directeur/Membre du Conseil chez
Q32 Bio, Inc.
Fortune : 13 260 $ au 31/05/2026
Profil
Sven Ante Lundberg is currently an Independent Director at Q32 Bio, Inc. since 2024 and a Director at Q32 Bio Operations, Inc. Former roles include President, CEO & Executive Director at Merus NV from 2023 to 2025; Independent Director at Vor Biopharma, Inc. from 2019 to 2025; Chief Scientific Officer at CRISPR Therapeutics AG from 2015 to 2018; Vice President & Head-Translational Medicine at Alexion Pharmaceuticals, Inc. from 2011 to 2015; Director & Chief Medical Officer at Taligen Therapeutics, Inc. from 2010 to 2012; Medical Director at Wyeth LLC and Genzyme Corp.; Director at Alliance for Regenerative Medicine; Principal at Antisoma Research Ltd. and Antisoma, Inc.; and Vice President-Clinical Development at Sarossa Capital Ltd. Education includes undergraduate studies at Massachusetts Institute of Technology, MBA degrees from the University of Massachusetts and The Isenberg School of Management, and a doctorate from Stanford University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,01 % | 12/06/2026 | 1 200 ( 0,01 % ) | 13 260 $ | 31/05/2026 |
Postes actifs de Bill Lundberg
| Sociétés | Poste | Début |
|---|---|---|
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Develops immunomodulatory therapies with protein based molecules using a platform | Directeur/Membre du Conseil | - |
Anciens postes connus de Bill Lundberg
| Sociétés | Poste | Fin |
|---|---|---|
| MERUS N.V. | Directeur Général | 12/12/2025 |
| VOR BIOPHARMA INC. | Directeur/Membre du Conseil | 17/07/2025 |
| CRISPR THERAPEUTICS AG | Directeur Technique/Scientifique/R&D | 08/02/2018 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2015 |
Taligen Therapeutics, Inc.
 Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops inflammatory disease pharamaceutical products | Directeur Technique/Scientifique/R&D | 24/02/2012 |
Formation de Bill Lundberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceuticals, vaccines & biotechnology products | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Antisoma Research Ltd. | |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops inflammatory disease pharamaceutical products | Health Technology |
Sarossa Capital Ltd.
 Sarossa Capital Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
Antisoma, Inc.
 Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and pharmaceuticals | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Massachusetts
 University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merus NV
 Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Isenberg School of Management
 The Isenberg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CRISPR Therapeutics AG
 CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Vor Biopharma, Inc.
 Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Develops immunomodulatory therapies with protein based molecules using a platform | Health Technology |
Choisissez Zonebourse 
